Oral Supplementation of Gangliosides to Treat a Rare Metabolic Disorder
NCT ID: NCT02234024
Last Updated: 2019-02-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2014-01-31
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Synergistic Enteral Regimen for Treatment of the Gangliosidoses
NCT02030015
Gene Therapy for Gaucher's and Fabry Disease Using Viruses and Blood-Forming Cells
NCT00001234
Effects of Enzyme Replacement in Gaucher's Disease
NCT00001289
Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease
NCT00004293
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease
NCT00465062
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Supplementation of gangliosides
Supplementation of dairy-derived concentrated gangliosides
Supplementation of dairy-derived concentrated gangliosides.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Supplementation of dairy-derived concentrated gangliosides.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
DDC Clinic - Center for Special Needs Children
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Heng Wang, MD PhD
Role: PRINCIPAL_INVESTIGATOR
DDC Clinic
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DDC-62314
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.